Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET

PurposeImaging biomarkers assessed with magnetic resonance imaging (MRI) and/or positron emission tomography (PET) enable non-invasive tumor characterization in cervix cancer patients. We investigated the spatio-temporal stability of hypoxia, perfusion, and the cell density of tumors over time by repetitive imaging prior to, during, and after radio-chemotherapy.ProceduresThirteen patients were included in this prospective study. The imaging protocol included the following: [18F]fluoromisonidazole ([18F]FMISO)-PET/x-ray computed tomography (CT) and multiparametric (mp)-MRI at four time-points (TP): baseline (BL); and weeks 2 (TP1), 5 (TP2), and 19 after treatment start (follow-up FU). Complete datasets for six patients could be assessed for tumor volume, enhancement kinetics, diffusivity, and [18F]FMISO-avidity (P1–P6). In addition, two patients completed all PET/CT examinations (P7–P8) but not all MR scans; however, one of them had no hypoxia (P8). Descriptive statistics, correlations, and voxel-by-voxel analysis were performed. For various, independent reasons, five patients could not complete the study according to the protocol with all imaging sequences.ResultsMedian tumor ADCs (in ×10−3 mm2/s) were 0.99 ± 0.10 at BL, 1.20 ± 0.12 at TP1, 1.33 ± 0.14 at TP2, and 1.38 ± 0.21 at FU. The median TBRpeak (tumor-to-background) was 2.7 ± 0.8 at BL, 1.6 ± 0.2 at TP1, 1.8 ± 0.3 at TP2, and 1.7 ± 0.3 at FU. The voxel-by-voxel analysis of the [18F]FMISO uptake at BL and TP1 showed no correlation. Between TP2 and TP1 and FU and TP2, weak correlations were found for two patients.ConclusionsLongitudinal mp-MR and PET imaging enables the in vivo tumor characterization over time. While perfusion and cell density decreased, there was a non-uniform change of hypoxia observed during radiotherapy. To assess the potential impact with regard to more personalized treatment approaches, hypoxia imaging-based dose painting for cervix cancer requires further research.

[1]  Michael Baumann,et al.  Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Heidi Lyng,et al.  Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  M. Mix,et al.  Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Ciprian Catana,et al.  Simultaneous PET-MRI in oncology: a solution looking for a problem? , 2012, Magnetic resonance imaging.

[5]  M. Schwaiger,et al.  Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry , 2017, Molecular Imaging and Biology.

[6]  A. W. Simonetti,et al.  Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2014, Magnetic resonance imaging.

[7]  Steen Jakobsen,et al.  FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Richard Pötter,et al.  MRI Assessment of Cervical Cancer for Adaptive Radiotherapy , 2009, Strahlentherapie und Onkologie.

[9]  Wade P. Smith,et al.  Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Christian Kirisits,et al.  Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. , 2005, International journal of radiation oncology, biology, physics.

[11]  John M Buatti,et al.  Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. , 2002, International journal of radiation oncology, biology, physics.

[12]  K Thielemans,et al.  Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET , 2010, Physics in medicine and biology.

[13]  Christian Kirisits,et al.  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  M. Picchio,et al.  Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  W Zhen,et al.  Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer , 2000, Journal of magnetic resonance imaging : JMRI.

[16]  Johannes A Langendijk,et al.  PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.

[17]  Dae Hyuk Moon,et al.  Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. , 2005, Nuclear medicine and biology.

[18]  R. Steenbakkers,et al.  PET-based analysis of tumor glucose metabolism and tumor hypoxia before and during anti-neoplastic treatment , 2015 .

[19]  N. deSouza,et al.  Diffusion-weighted magnetic resonance imaging and its application to cancer , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[20]  M. Schwaiger,et al.  Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[21]  Jian Z. Wang,et al.  Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer , 2009, Investigative radiology.

[22]  Young-Bin Cho,et al.  Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. , 2008, International journal of radiation oncology, biology, physics.

[23]  Werner Vach,et al.  Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  T. Yankeelov,et al.  Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer , 2017, Molecular Imaging and Biology.

[25]  Jian Z. Wang,et al.  Ultra‐early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer , 2010, Cancer.

[26]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[27]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Richard Pötter,et al.  Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer , 2010, Acta oncologica.

[29]  Andras Lasso,et al.  SlicerRT: radiation therapy research toolkit for 3D Slicer. , 2012, Medical physics.

[30]  P. Pauwels,et al.  Baseline [18F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model , 2016, Molecular Imaging and Biology.

[31]  B. K. Park,et al.  Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T. , 2015, Radiology.

[32]  R. Steenbakkers,et al.  Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET: A Review , 2014, Clinical nuclear medicine.

[33]  Helmar Bergmann,et al.  PET based volume segmentation with emphasis on the iterative TrueX algorithm. , 2012, Zeitschrift fur medizinische Physik.

[34]  Takeo Ishigaki,et al.  Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix , 2004, European Radiology.

[35]  Wolfgang Wadsak,et al.  Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study , 2016, PloS one.